Physician profile
Jun H Kong
NPI 1225092984
$12,198.36
in general payments reported to CMS, 2019-2025
46 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $1,209 · 2021: $1,716 · 2022: $1,293 · 2023: $2,282 · 2024: $2,070 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,371.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,235.53 | 2021-2025 | |
| Lilly USA, LLC | $1,147.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $690.60 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $567.54 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $516.32 | 2020-2024 | Spravato, Xarelto |
| Amgen INC. | $510.97 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.32 | 2019-2025 | Xifaxan |
| Pfizer INC. | $467.24 | 2019-2025 | |
| Gilead Sciences, INC. | $452.41 | 2019-2025 | |
| Abbott Laboratories | $422.57 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $335.68 | 2019-2022 | |
| Viiv Healthcare Company | $206.11 | 2022-2025 | Apretude |
| Otsuka America Pharmaceutical, INC. | $203.56 | 2021-2025 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.